Covid-19: Cytokine storm and Coagulopathy biomarkers, IL-6 and D-Dimer, well managed with Nichi-Glucan REFIX in clinical study: https://www.medrxiv.org/content/10.1101/2021.08.09.21261738v1
Neu REFIX beta glucans improving Multiple Sclerosis patients’ gut microbiome awarded as the best poster
Nichi BRITE Beta glucans yileding clinically encouraging outcome in a trial was presented in the webinar that commemorated World Parkinsons Day held on the 10th April 2023
Neurology Live, a clinical neurologists focused media portal has published GN Corporation’s presentation at the MDA on the Clinical trial results of Neu REFIX in Duchenne Muscular Dystrophy
GN Corporation will present the results of preclinical and clinical studies with neu REFIX (N-163), one of its
Manuscript published in Stem Cell Reviews and Reports
Technology transfer on cell therapy to Vietnam by GN Corporation leads to new opportunities
Webiner on Cell Therapy Approaches for Urethral Stricture is held on 16 OCt 2022
A look at the potential of beta-glucan for the growing number of non-alcoholic fatty liver diseases
